vs
BIOCRYST PHARMACEUTICALS INC（BCRX）与Rubrik, Inc.（RBRK）财务数据对比。点击上方公司名可切换其他公司
BIOCRYST PHARMACEUTICALS INC的季度营收约是Rubrik, Inc.的1.2倍（$406.6M vs $350.2M），BIOCRYST PHARMACEUTICALS INC净利率更高（60.5% vs -18.2%，领先78.7%），BIOCRYST PHARMACEUTICALS INC同比增速更快（209.1% vs 48.3%），BIOCRYST PHARMACEUTICALS INC自由现金流更多（$291.2M vs $80.7M）
BioCryst Pharmaceuticals是一家总部位于美国北卡罗来纳州达勒姆的制药企业，属于后期发展阶段的生物科技公司，聚焦于治疗罕见重症的口服药物研发。其研发的抗病毒药物帕拉米韦（商品名Rapivab）于2014年12月获得美国FDA批准，此后也陆续在日本、韩国与中国获批上市。
Rubrik是总部位于美国加利福尼亚州帕洛阿尔托的云数据管理与数据安全企业，成立于2014年1月，专注于为客户提供云环境下的数据管理、安全防护相关解决方案，2024年4月在纽约证券交易所上市。
BCRX vs RBRK — 直观对比
营收规模更大
BCRX
是对方的1.2倍
$350.2M
营收增速更快
BCRX
高出160.8%
48.3%
净利率更高
BCRX
高出78.7%
-18.2%
自由现金流更多
BCRX
多$210.4M
$80.7M
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $406.6M | $350.2M |
| 净利润 | $245.8M | $-63.8M |
| 毛利率 | 97.7% | 80.5% |
| 营业利润率 | 64.0% | -21.6% |
| 净利率 | 60.5% | -18.2% |
| 营收同比 | 209.1% | 48.3% |
| 净利润同比 | 1017.5% | 51.2% |
| 每股收益（稀释后） | $1.13 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BCRXRBRK
| Q4 25 | $406.6M | $350.2M | ||
| Q3 25 | $159.4M | $309.9M | ||
| Q2 25 | $163.4M | $278.5M | ||
| Q1 25 | $145.5M | $258.1M | ||
| Q4 24 | $131.5M | $236.2M | ||
| Q3 24 | $117.1M | $205.0M | ||
| Q2 24 | $109.3M | $187.3M | ||
| Q1 24 | $92.8M | — |
净利润BCRXRBRK
| Q4 25 | $245.8M | $-63.8M | ||
| Q3 25 | $12.9M | $-95.9M | ||
| Q2 25 | $5.1M | $-102.1M | ||
| Q1 25 | $32.0K | $-114.9M | ||
| Q4 24 | $-26.8M | $-130.9M | ||
| Q3 24 | $-14.0M | $-176.9M | ||
| Q2 24 | $-12.7M | $-732.1M | ||
| Q1 24 | $-35.4M | — |
毛利率BCRXRBRK
| Q4 25 | 97.7% | 80.5% | ||
| Q3 25 | 98.6% | 79.5% | ||
| Q2 25 | 98.3% | 78.3% | ||
| Q1 25 | 96.9% | 77.4% | ||
| Q4 24 | 95.4% | 76.2% | ||
| Q3 24 | 97.3% | 73.1% | ||
| Q2 24 | 98.4% | 48.8% | ||
| Q1 24 | 98.6% | — |
营业利润率BCRXRBRK
| Q4 25 | 64.0% | -21.6% | ||
| Q3 25 | 18.6% | -30.5% | ||
| Q2 25 | 18.2% | -33.4% | ||
| Q1 25 | 14.6% | -45.0% | ||
| Q4 24 | -3.4% | -52.8% | ||
| Q3 24 | 6.6% | -82.1% | ||
| Q2 24 | 8.0% | -387.0% | ||
| Q1 24 | -15.6% | — |
净利率BCRXRBRK
| Q4 25 | 60.5% | -18.2% | ||
| Q3 25 | 8.1% | -31.0% | ||
| Q2 25 | 3.1% | -36.7% | ||
| Q1 25 | 0.0% | -44.5% | ||
| Q4 24 | -20.4% | -55.4% | ||
| Q3 24 | -12.0% | -86.3% | ||
| Q2 24 | -11.6% | -390.8% | ||
| Q1 24 | -38.1% | — |
每股收益（稀释后）BCRXRBRK
| Q4 25 | $1.13 | $-0.32 | ||
| Q3 25 | $0.06 | $-0.49 | ||
| Q2 25 | $0.02 | $-0.53 | ||
| Q1 25 | $0.00 | $5.69 | ||
| Q4 24 | $-0.13 | $-0.71 | ||
| Q3 24 | $-0.07 | $-0.98 | ||
| Q2 24 | $-0.06 | $-11.48 | ||
| Q1 24 | $-0.17 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $274.7M | $307.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-119.2M | $-524.4M |
| 总资产 | $514.2M | $2.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BCRXRBRK
| Q4 25 | $274.7M | $307.1M | ||
| Q3 25 | $212.9M | $322.7M | ||
| Q2 25 | $260.0M | $284.0M | ||
| Q1 25 | $295.1M | $186.3M | ||
| Q4 24 | $320.9M | $103.9M | ||
| Q3 24 | $96.8M | $142.3M | ||
| Q2 24 | $78.4M | $502.6M | ||
| Q1 24 | $84.3M | — |
股东权益BCRXRBRK
| Q4 25 | $-119.2M | $-524.4M | ||
| Q3 25 | $-387.9M | $-564.3M | ||
| Q2 25 | $-421.6M | $-556.5M | ||
| Q1 25 | $-451.9M | $-553.7M | ||
| Q4 24 | $-475.9M | $-521.1M | ||
| Q3 24 | $-468.6M | $-499.3M | ||
| Q2 24 | $-475.6M | $-514.6M | ||
| Q1 24 | $-476.2M | — |
总资产BCRXRBRK
| Q4 25 | $514.2M | $2.5B | ||
| Q3 25 | $446.4M | $2.4B | ||
| Q2 25 | $457.2M | $1.5B | ||
| Q1 25 | $480.0M | $1.4B | ||
| Q4 24 | $490.4M | $1.3B | ||
| Q3 24 | $491.3M | $1.2B | ||
| Q2 24 | $472.4M | $1.2B | ||
| Q1 24 | $467.9M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $292.0M | $85.5M |
| 自由现金流经营现金流 - 资本支出 | $291.2M | $80.7M |
| 自由现金流率自由现金流/营收 | 71.6% | 23.1% |
| 资本支出强度资本支出/营收 | 0.2% | 1.4% |
| 现金转化率经营现金流/净利润 | 1.19× | — |
| 过去12个月自由现金流最近4个季度 | $344.9M | $256.8M |
8季度趋势，按日历期对齐
经营现金流BCRXRBRK
| Q4 25 | $292.0M | $85.5M | ||
| Q3 25 | $41.6M | $64.7M | ||
| Q2 25 | $41.3M | $39.7M | ||
| Q1 25 | $-27.5M | $83.6M | ||
| Q4 24 | $-5.2M | $23.1M | ||
| Q3 24 | $8.2M | $-27.1M | ||
| Q2 24 | $-1.4M | $-31.4M | ||
| Q1 24 | $-53.7M | — |
自由现金流BCRXRBRK
| Q4 25 | $291.2M | $80.7M | ||
| Q3 25 | $40.3M | $61.2M | ||
| Q2 25 | $41.1M | $36.8M | ||
| Q1 25 | $-27.7M | $78.0M | ||
| Q4 24 | $-5.9M | $18.0M | ||
| Q3 24 | $8.2M | $-29.7M | ||
| Q2 24 | $-1.5M | $-35.0M | ||
| Q1 24 | $-53.9M | — |
自由现金流率BCRXRBRK
| Q4 25 | 71.6% | 23.1% | ||
| Q3 25 | 25.3% | 19.8% | ||
| Q2 25 | 25.2% | 13.2% | ||
| Q1 25 | -19.0% | 30.2% | ||
| Q4 24 | -4.5% | 7.6% | ||
| Q3 24 | 7.0% | -14.5% | ||
| Q2 24 | -1.4% | -18.7% | ||
| Q1 24 | -58.1% | — |
资本支出强度BCRXRBRK
| Q4 25 | 0.2% | 1.4% | ||
| Q3 25 | 0.8% | 1.1% | ||
| Q2 25 | 0.1% | 1.0% | ||
| Q1 25 | 0.1% | 2.2% | ||
| Q4 24 | 0.5% | 2.1% | ||
| Q3 24 | 0.1% | 1.3% | ||
| Q2 24 | 0.1% | 1.9% | ||
| Q1 24 | 0.3% | — |
现金转化率BCRXRBRK
| Q4 25 | 1.19× | — | ||
| Q3 25 | 3.23× | — | ||
| Q2 25 | 8.12× | — | ||
| Q1 25 | -859.91× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BCRX
暂无分部数据
RBRK
| Subscription And Circulation | $336.4M | 96% |
| Other | $12.3M | 4% |
| Software And Services | $4.9M | 1% |
| Maintenance | $1.5M | 0% |
